REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 25th, 2008 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 25th, 2008 Company Industry Jurisdiction
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • November 25th, 2008 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 25th, 2008 Company Industry JurisdictionThis AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (this "Amendment") is entered into as of November 19, 2008 and shall be effective as of October 1, 2008, by and between Manhattan Pharmaceuticals, Inc. (the "Company") and Douglas Abel (the "Executive").
SECURITY AGREEMENTSecurity Agreement • November 25th, 2008 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 25th, 2008 Company Industry JurisdictionTHIS SECURITY AGREEMENT (the “Security Agreement”) is dated as of November 19, 2008 by and among Manhattan Pharmaceuticals, Inc., a Delaware corporation (the “Company” or the “Debtor”) and each of the persons named on Exhibit A-1 and Exhibit A-2 of the SPA (as hereinafter defined) (each a “Secured Party” and, collectively, the “Secured Parties”).
DEFAULT AGREEMENTDefault Agreement • November 25th, 2008 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 25th, 2008 Company Industry JurisdictionDefault Agreement, dated as of November 19, 2008, by and among Manhattan Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, with a principal address at 48 Wall Street, Suite 1100, New York, New York 10005, and the persons and entities listed on Schedule A hereto (individually, a “Lender” and, collectively, the “Lenders”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 25th, 2008 • Manhattan Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 25th, 2008 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 19, 2008, by and between Manhattan Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the investors (each, an “Investor” and, collectively, the “Investors”), set forth on Exhibit A-1 and Exhibit A-2.